In a report released today, Serge Belanger from Needham maintained a Buy rating on Aerie Pharma (AERI – Research Report), with a price target of $22.00. The company’s shares closed last Thursday at $7.46, close to its 52-week low of $6.67.
According to TipRanks.com, Belanger is a 1-star analyst with an average return of -0.3% and a 37.3% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical.
Currently, the analyst consensus on Aerie Pharma is a Moderate Buy with an average price target of $21.00.
The company has a one-year high of $21.30 and a one-year low of $6.67. Currently, Aerie Pharma has an average volume of 1.14M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.
Read More on AERI:
- Equinox Gold (EQX) Received its Third Buy in a Row
- Jefferies Believes Bayerische Motoren Werke Aktiengesellschaft (BAMXF) Won’t Stop Here
- BMO Capital Sticks to Their Buy Rating for 9 Meters Biopharma (NMTR)
- Corus Entertainment (CJREF) Gets a Hold Rating from BMO Capital
- Yamana Gold (AUY) Gets a Buy Rating from BMO Capital